(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)
* U.S. weekly jobless claims fall for third straight week
* Gilead’s coronavirus drug flops in first trial -FT
* Indexes: Dow +0.17%, S&P 500 -0.05%, Nasdaq -0.01% (Updates with close of trading)
By Noel Randewich
April 23 (Reuters) - The S&P 500 ended marginally lower on Thursday after a report that an experimental antiviral drug for the coronavirus flopped in its first randomized clinical trial, denting earlier optimism that the impact of the pandemic on the labor market was nearing an end.
All three main U.S. stock indexes fell back from gains of over 1% after the Financial Times reported that a Chinese trial showed that Gilead Science’s remdesivir did not improve patients’ condition or reduce the pathogen’s presence in the bloodstream.
Gilead said the results from the study were inconclusive as it was terminated early.
Last Friday, Wall Street rallied in part because of a report that COVID-19 patients in a separate study had responded positively to remdesivir.
The market’s sensitivity to news related to coronavirus therapies reflects investors’ desperation for any indication of when the global economy might be able to start returning to normal.
“The hope as of last week was that Gilead could take the fear of dying off the table, which would result in a much quicker, cleaner, faster recovery. If that’s less likely today than it was yesterday, it is perfectly reasonable for the market to have sold off,” said David Katz, chief investment officer at Matrix Asset Advisors.
Stocks rallied earlier in the session after data that showed weekly U.S. jobless claims fell to 4.43 million from a revised 5.24 million. However, the numbers were still staggering, taking the total in the past five weeks to a record 26 million and wiping out all the jobs created since the financial crisis.
“The disappointing drug news stings, but considering another 4 million people lost their jobs, the disconnect between how well stocks have held up in the face of historically bad economic data continues,” said Ryan Detrick, senior market strategist at LPL Financial.
Meanwhile, the U.S. Congress was preparing nearly $500 billion more in aid for small businesses and hospitals, which was expected to clear the House of Representatives later in the day.
The energy index rose 3%, easily leading the 11 S&P 500 sectors as oil prices recovered in a tumultuous week that saw U.S. crude futures crash below zero for the first time in history.
U.S. stock indexes have rallied this month on a raft of global stimulus, but the benchmark S&P 500 remains more than 15% below its record high as worsening economic indicators foreshadow a deep global recession.
A survey showed U.S. business activity plumbed new record lows in April, mirroring dire figures from Europe and Asia as strict stay-at-home orders crushed production, supply chains and consumer spending.
The CBOE volatility index has retreated from 12-year peaks hit last month, but remains well above levels seen in the past two years and analysts have warned of another sell-off as corporate America issues worrying forecasts for the year.
The Dow Jones Industrial Average rose 0.17% to end at 23,515.26 points, while the S&P 500 lost 0.05% to finish at 2,797.8.
The Nasdaq Composite slipped 0.01% to 8,494.75.
Las Vegas Sands Corp jumped 12% after the casino operator predicted a speedy recovery in Asia on pent-up gambling demand.
Advancing issues outnumbered declining ones on the NYSE by a 1.64-to-1 ratio; on Nasdaq, a 1.50-to-1 ratio favored advancers.
The S&P 500 posted six new 52-week highs and one new low; the Nasdaq Composite recorded 36 new highs and 21 new lows.
Volume on U.S. exchanges was 11.7 billion shares, compared with a 12.7 billion-share average over the last 20 trading days. (Reporting by Noel Randewich in New York and Shreyashi Sanyal and C Nivedita in Bengaluru; Editing by Will Dunham and Jonathan Oatis)